| Literature DB >> 31392217 |
Ksenia Loskutova1, Dmitry Grishenkov1, Morteza Ghorbani1,2.
Abstract
Acoustic droplet vaporization (ADV) is the physical process in which liquid undergoes phase transition to gas after exposure to a pressure amplitude above a certain threshold. In recent years, new techniques in ultrasound diagnostics and therapeutics have been developed which utilize microformulations with various physical and chemical properties. The purpose of this review is to give the reader a general idea on how ADV can be implemented for the existing biomedical applications of droplet vaporization. In this regard, the recent developments in ultrasound therapy which shed light on the ADV are considered. Modern designs of capsules and nanodroplets (NDs) are shown, and the material choices and their implications for function are discussed. The influence of the physical properties of the induced acoustic field, the surrounding medium, and thermophysical effects on the vaporization are presented. Lastly, current challenges and potential future applications towards the implementation of the therapeutic droplets are discussed.Entities:
Mesh:
Year: 2019 PMID: 31392217 PMCID: PMC6662494 DOI: 10.1155/2019/9480193
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1The manufacturing process of PCAs using the “condesation” method. The capsule with gas content is exposed to lowered temperature and increased ambient pressure, forcing the core material to phase transit to a liquid. The perfluorocarbon core is superheated, so the nanodroplet will be stable. The core will undergo phase transition back to gas after ultrasound exposure or if the temperature is significantly increased above the boiling point. Reprinted (adapted) with premission from [18]. Copyright 2011 American Chemical Society.
Droplet fabrication method, significances and specifications used in bubble activation.
| Study | Core material | Shell | Fabrication method | Size before ADV | Size after ADV | Significance | Future potential |
|---|---|---|---|---|---|---|---|
| Li et al. [ | Perfluoropentane | Albumin | Mixing Saline containing PBS albumin and perfluoropentane | Various sizes of micrometer scale | 36 | A model that describes the location of initial nucleation site in liquid PFC droplets depending on droplet size and acoustic characteristics | The initial nucleation site always occurs within the droplet and not at the bubble-surface interface |
|
| |||||||
| Miles et al. [ | Perfluoropentane | Lipids | NA | 3-30 | NA | Possible to predict ADV initiation pressure threshold by combining classical nucleation theory with superharmonic focusing | Customize droplet size and/or pressure in advance depending on the application |
|
| |||||||
| Strohm et al. [ | Perfluorohexane | Fluorosurfactant (Zonyl FSO) | Coarse emulsification by vortexing, followed by membrane emulsification | 2.45-13.6 | NA | Only the physical properties of the PFH liquid determines the droplet photoacoustic spectrum features | Proof of concept |
|
| |||||||
| Doinikov et al. [ | Octafluoropropane and decafluorobutane | 1,2-distearyl-sn-glycero-3-phosphocholine, DSPE-PEG2000 | Condensation | 2.2-6.7 | Up to 40 | A new model that describes the dynamic behavior of highly volatile perfluorocarbon emulsions, which was in good agreement with experimental results | Predict the behavior of highly volatile perfluorocarbon emulsions at various acoustic parameter values |
|
| |||||||
| Lin et al. [ | Decafluorobutane | DPPC, 16:0 PEG2000 PE | Condensation | 243 nm | 1.22 | PCCAs in microchannel will have a lower vaporization efficiency than PCCAs in free environment at the same acoustic conditions | Higher validity in conclusions drawn from images with microvasculature |
|
| |||||||
| Sheeran et al. [ | Perfluoropropane or perfluorobutane | 1,2-distearoyl-sn-glycero-3-phosphocholine, DSPE-PEG2000 | Condensation | 192 nm | 1.2 | Unique acoustic signals are generated by vaporizing phase-change droplets that can be detected and isolated from other acoustic sources | Combine different imaging modalities for optimal diagnostics |
|
| |||||||
| Puett et al. [ | Decafluorobutane or octafluoropropane | DSPC, DSPE-PEG2000 | Condensation | 240 nm | NA | A new pulse sequence design that enables fast image-activation-image process | Fast and easy study of ADV activated droplets in research |
|
| |||||||
| Li et al. [ | Decafluorobutane | Lipids | Condensation | 230-350 nm | 5-6.5 | Linear relationship between droplet concentration and activation; at room temperature, the bubbles were fewer and larger compared to body temperature | Control of droplet concentrations in applications that use inertial cavitation |
|
| |||||||
| Reznik et al. [ | Perfluoropentane | Fluorosurfactant (Zonyl FSO) | Tip-sinocation approach | 400 nm | 500 nm - 5 | The coating material highly influence the acoustic behavior of vaporized PFC droplets | Fluorosurfactant-coated droplets has potential as contrast agents in ultrasound imaging |
Vaporization pressure and frequency range corresponding to common cavitation types in acoustic droplet vaporization.
| Cavitation type | Vaporization frequency | Vaporization pressure | Imaging frequency | Application | Study |
|---|---|---|---|---|---|
| Stable | 5 MHz | 3.5 MPa | 2.5 MHz (acoustic characterization) | Bubble activation | Reznik et al. [ |
| 5 MHz | 2.5-4 MPa | NA | Capsule design; Diagnostics | Martz et al. [ | |
| 7.5 MHz | Depends on droplet size | 7.5 MHz | Bubble activation | Li et al. [ | |
| 7.5 MHz | Depends on droplet size | NA | Bubble activation | Miles et al. [ | |
| 7.5 MHz | 1.6 MPa | NA | DIagnostics; Theranostics | Jin et al. [ | |
| 8 MHz | 500 kPa | 4.5 MHz | Bubble activation; Diagnostics | Doinikov et al. [ | |
| 8 MHz | 3.39 MPa | 4.5 MHz | Diagnostics; Drug delivery | Lin et al. [ | |
| 8 MHz | 4.81 MPa | 1 MHz (passive recording) | Bubble activation | Lin et al. [ | |
| 8 MHz | 2.5 MPa (for OFP), 3.7-4.2 MPa (for DFB) | 7 MHz; 14MHz | Diagnostics | Lin et al. [ | |
| 8 MHz | 3.1 MPa | NA | Diagnostics | Paul S. Sheeran et al. [ | |
| 9 MHz | 3.7-8.7 MPa (for DFB), 3.1-7.4 MPa (for OFP) | 4.5 MHz | Bubble activation; Diagnostics | Puett et al. [ | |
|
| |||||
| Inertial | 1 MHz | 4.41 MPa | NA | Drug delivery | VanOsdol et al. [ |
| 1.5 MHz | 90 W (for vaporization), 5.2-38.5 W (for inertial cavitation) | NA | Thermal therapy | Kopechek et al. [ | |
| 1.14 MHz | 4 MPa | NA | Thermal therapy | Moyer et al. [ | |
| 2 MHz | NA | 2 MHz | Drug delivery | Duncanson et al. [ | |
| 2.25 MHz | 12 V | NA | Drug delivery | Soto et al. [ | |
| 1.44 MHz | 7.4 MPa | NA | Thermal therapy | Kripfgans et al. [ | |
| 2 MHz | 7-10 MPa | 5 MHz (passive cavitation detection), 2.25 MHz (attenuation) | Vascular therapy | Kang et al. [ | |
| 1.513 MHz | 5.8 MPa (in vitro), 88 W (in vivo) | NA | Vascular therapy | Pajek et al. [ | |
Droplet fabrication method, significances, and specifications used in vascular therapy.
| Study | Core material | Shell | Fabrication method | Size before ADV | Size after ADV | Significance | Future potential |
|---|---|---|---|---|---|---|---|
| Samuel et al. [ | Perfluoropentane | Albumin | Based on mixing saline containing bovine serum albumin and perfluoropentane | 2 | 76 × 36 | Vaporizing in the capillaries causes vessel damage and subsequent leakage of blood cells, but no vessel damage was seen for the feeder vessel | Further improve and optimize gas embolotherapy using ADV-generated PFC bubbles |
|
| |||||||
| Kang et al. [ | Perfluoropentane | DPPC, DSPE-PEG2000, cholesterol | Sonication of a vial containing shell mixture and perfluoropentane | 1.3 | Up to 8 | Possible to predict the mechanical damage severity as a function of droplet vaporization, PNP, phantom stiffness, pulse duration and PRF | Improved control of damage done by ADV in medical applications |
|
| |||||||
| Seda et al. [ | Perfluoropentane | Albumin | Sonication of a vial containing shell mixture and perfluoropentane | 1.6 | NA | Viability of endothelial cells is lower at the ADV bubble site than at other regions | Control of damage during gas embolotherapy |
|
| |||||||
| Pajek et al. [ | Perfluoropentane | Fluorosurfactant (Zonyl FSO) | Sonication of a vial containing shell mixture and perfluoropentane | 136-152 nm (in vitro), 156-207 nm (in vivo) | NA | A lower pressure amplitude is sufficient to induce inertial cavitation if droplets with perfluorocarbon is present in sonothrombolysis | Reduced risk of thermal damage in healthy tissue while efficient sonothrombolysis |
Figure 2The concept of localized drug delivery to poorly perfused regions. DiI is a red fluorescent dye used to observe the intratumoral distribution. Reprinted (adapted) with premission from [20]. Copyright 2017 American Chemical Society.
Droplet fabrication method, significances and specifications used in drug delivery.
| Study | Core material | Shell | Fabrication method | Size before ADV | Size after ADV | Significance | Future potential |
|---|---|---|---|---|---|---|---|
| Ho et al. [ | Perfluoropentane | DPPC, DSPG, DSPE-PEG5000 | Condensation | 214 nm | 100% of vessels with diameters below 10 | Drug-loaded capsules are used to disrupt blood vessels and deliver drugs locally to a tumor | Improved tumor treatment by obstructing blood flow and causing direct damage |
|
| |||||||
| VanOsdol et al. [ | Perfluoropentane | DPPC, MSPC, DSPE-mPEG2000; NTSL: DPPC, cholesterol, DSPE-mPEG2000 | Extrusion method for synthesizing lipid shell and pH-gradient loading protocol for droplet preparaion | 170-190 nm | NA | Echogenic low temperature sensitive liposomes are effective for drug delivery when paired with sequential HIFU heating for short duration time | Improved treatment of difficult cancers, such as lvier and colon |
|
| |||||||
| Rapoport et al. [ | Perfluoropentane | Block polymer stabilized micelles | A solvent exchange echnique for micellar solution and transferring PFP to the sonicated shell | Three peaks: 19.3-29.3 nm, 114.7-188.9 nm, 592.6-718.4 nm | Up to 10 | Drug-loaded emulsions combined with HIFU can be effective when treating ovarian, breat and pancreatic cancer | Need to study cell resistance, since second treatment was not at all as efficient as the first one |
|
| |||||||
| Fix et al. [ | Perfluoropropane | DSPC, DSPE-PEG2000 | Condensation | 140 nm | 1-10 | Low-boiling PCCAs induce cellular sonoporation, and efficiency of sonoporation increase with increasing PNP and increasing pulse length | Improved drug or gene delivery |
|
| |||||||
| Soto et al. [ | Perfluorocarbon | DSPC, mPEG-DSPE | Evaporation of the mixed nanoemulsion with the use of an ultrasound probe generator | NA | NA | The patch loaded with lidocaine and PFC emulsions and exposed to US increased the payload skin penetration compared to passive diffusion | New way to deliver local anesthetics over a long time |
|
| |||||||
| Ho et al. [ | Perfluoropentane | DPPC, DSPG, DSPE-PEG2000 | Condensation | 1.1 | 10-15 | Vascular disruption induced by ADV with multiple US sonications improves drug penetration more than the EPR effect | Better drug delivery optimization |
Figure 3Ultrasound B-mode (left) and contrast-enhanced ultrasound mode (right) images of peptide-functionalized drug-loaded nanoparticles at different time points of various LIFU settings. At high enough power, the nanoparticles exploded, which could be seen as a decrease in signal intensity at 2.8 W/cm2. Reprinted (adapted) with premission from [81]. Copyright 2018 American Chemical Society.
Summary of studies on attempts for improvement in acoustic droplet vaporization.
| Purpose | Advantage in relation to ADV | Outcome | Application | Droplet core and specification | Study |
|---|---|---|---|---|---|
| Fabrication of novel ultrasound molecular probe | Use of low-intensity focused US (LIFU) sonication for the regular ultrasound visualization | Notable ultrasound contrast enhancement in the tumor region | Tumor molecular imaging | Folate-targeted; Perfluoropentane | Liu et al. [ |
|
| |||||
| Synthesize a targeted computed tomography (CT) perfluorooctylbromide nanoparticle for the early detection of ovarian cancer | Successful targeted drug delivery | High efficiency in terms of targeting and long circulation time of the synthesized droplets | Detection of ovarian cancer | Folate-receptor-targeting; Perfluorooctylbromide | Liu et al. [ |
|
| |||||
| Fabrication of droplets with size control using microfluidics | Viability of the droplets for the in situ production of ultrasound contrast agents as a echogenic bubbles | Fabrication of droplets have a size of 24 times smaller than the precursor bubbles | Cancer imaging and therapy | Monodisperse; Cosolvent-incorporated; Perfluorocarbon | Seo et al. [ |
|
| |||||
| Fabrication of a multifunctional targeted poly(lactic-co-glycolic acid) (PLGA) nanobubbles for tumor imaging and HIFU ablation | The combination of HIFU ablation and chemotherapy with the aid of the developed NBs suits well with several therapeutic and diagnostic treatments | The change in the acoustic environment leads to improve the efficiency of HIFU ablation when the fabricated NBs are using | Tumor imaging; Anti-cancer drug carrier; Synergistic agent for enhancing therapeutic efficiency | Methotrexate (MTX)-loaded NBs filled with perfluorocarbon | Zhang et al. [ |
|
| |||||
| Targeted gas embolotherapy with the aid of ADV | The feasibility of occluding vessels with in the embolotherapy with the use of ADV | The successful utilization of gas embolotherapy as an noninvasive method for the treatment of unresectable hepatocellular carcinoma | Hepatocellular carcinoma | Perfluoropentane | Harmon et al. [ |
|
| |||||
| Locally enhance energy absorption and heating in the focused ultrasound | Suitability of the nanoemulsion in the thermal FUS therapies | Enhancement of acoustic cavitation and temperature rise in an in vitro study with the use of phase-shift nanoemulsions (PSNE) | Thermal focused ultrasound therapy | Perfluoropentane | Crake et al. [ |
|
| |||||
| To lower the power output and radiation time during radiofrequency (RF) ablation | Using the versatility of radiofrequency solidoid vaporization to compensate drawbacks and limitations of ADV and optical droplet vaporization (ODV) | Employment of continuous cavitation to enhance the RF ablation | Cancer theranostics | Perfluorocarbon-encapsulated theranostic agents | Zhang et al. [ |